Venn Life Sciences Holdings Plc
("Venn" or the "Company" or the "Company")
Notice of AGM and Posting of Annual Report and Accounts
Venn Life Sciences (AIM: VENN), an Integrated Drug Development Partner offering a combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device clients, announces that the Annual Report and Accounts for the year ended 31 December 2017 have been posted to shareholders, together with Notice of the Annual General Meeting and a Form of Proxy.
The Annual General Meeting is to be held on Wednesday 27 June 2018 at 12 noon at the Heathrow Marriot, Bath Rd, Harlington, Hayes, UB3 5AN.
The Annual Report and Accounts and the Notice of Annual General Meeting will be on the website at www.vennlifesciences.com/investors
Enquiries:
|
Venn Life Sciences Holdings Plc |
Tel: +353 1 549 9341 |
||
|
Allan Wood, Non-Executive Chairman |
|||
|
Tony Richardson, Chief Executive Officer |
|||
|
Cenkos (Nominated Advisor and Co-Broker) |
Tel: +44 (0) 20 7397 8900 |
||
|
Mark Connelly/Steve Cox (Corporate Finance) |
|||
|
Davy (ESM Adviser and Co-Broker) |
|||
|
Fergal Meegan / Matthew de Vere White (Corporate Finance) |
Tel: +353 1 679 6363 |
||
|
Hybridan (Co-Broker) |
|||
|
Claire Louise Noyce |
Tel: +44(0) 20 3764 2341 |
||
|
Walbrook PR Ltd |
Tel: +44(0)20 7933 8787 |
||
|
Paul McManus/ Anna Dunphy |
|||
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.